Authors

Latest:

Blackwell Explores Emerging Trends in Treating HER2 Metastatic Breast Cancer

Since its approval in 1998 to treat metastatic breast cancer, the anti-HER2 monoclonal antibody trastuzumab has dramatically expanded life expectancy and improved quality of life for women diagnosed with HER2-positive disease.

Tracey Ryan

Latest:

Payer Management of Oncology Gets Serious

Health plans continue to seek methods to curtail cancer costs.

Traci L. Hedrick, MD, MS

Latest:

Enhanced Recovery Program Improves Outcomes After Colorectal Cancer Surgery

The adoption of enhanced recovery after surgery protocols can improve not only the outcomes of patients after a procedure but can also reduce hospital costs, as has been seen in an ERAS program in colorectal cancer at the University of Virginia Health System.

Tracy Regan

Latest:

Payers Try to Drive Down Costs in Cancer Care

Steadily rising expenses and a proliferation of new drugs are speeding adoption of a host of measures designed to contain drug and treatment outlays more directly

Translational Science Institute

Trine Alma Knudsen, MD, PhD

Latest:

Dr. Knudsen Discusses the Rationale of the DALIAH Trial in MPNs

Trine Alma Knudsen, MD, PhD student, Department of Haematology, Zealand University Hospital, Roskilde, Denmark, discusses the rationale of the DALIAH trial in patients with myeloproliferative neoplasms.

Trung Nguyen, DO, MBA

Latest:

Dr. Nguyen on Treatment Approaches for Patients With Advanced Ovarian Cancer

Trung Nguyen, DO, MBA, clinical assistant professor, Obstetrics and Gynecology, Gynecologic Oncology, Stanford Medicine, discusses treatment approaches for patients with advanced ovarian cancer.

T.S. Wiley

Latest:

T.S. Wiley on Bio-identical Hormone Replacement Therapy for Patients With Breast Cancer

T.S. Wiley, CEO, Wiley Protocol Systems, discusses a study that examined the efficacy of biomemetic bio-identical hormone replacement therapy for patients with metastatic breast cancer.

Tsiporah B. Shore, MD

Latest:

Dr. Shore on Stem Cell Transplant in Ethnic Populations

Tsiporah B. Shore, MD, associate director of the Blood and Bone Marrow Transplant Program of Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses stem cell transplantation in patients with hematologic malignancies and are of ethnic populations.

Tycel J. Phillips, MD

Latest:

Dr Phillips on the Rationale of Evaluating Glofitamab in R/R Mantle Cell Lymphoma

Tycel Phillips, MD, MPH, discusses the rationale of the phase 1/2 NP30179 trial evaluating glofitamab in relapsed/refractory mantle cell lymphoma.

Tycel Jovelle Phillips, MD, University of Michigan

Latest:

Dr. Phillips on the Current Role of Ibrutinib in MCL

Tycel Jovelle Phillips, MD, discusses the current role of ibrutinib in mantle cell lymphoma.

Tyler Greer

Latest:

Sleckman to lead O'Neal Comprehensive Cancer Center

Barry Paul Sleckman, MD, PhD, has been named director of the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham.

UC San Diego Health

UCS

Udai Banerji, MD

Latest:

Dr. Banerji on the Clinical Activity of VS-6766/Defactinib in KRAS-Mutant Tumors

Udai Banerji, MD, discusses the results from a phase 1 trial with the combination of VS-6766 (CH5126766) and defactinib in KRAS-mutant tumors.

Udit Verma, MD

Latest:

Dr. Udit Verma on Managing Regorafenib Side Effects in CRC

Ulka Vaishampayan, MD

Latest:

Triple Combination Therapies in RCC: Clinical Trial Insights

Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.

Ulka Vaishampayan, MD, Barbara Ann Karmanos Cancer Institute

Ulka Vaishampayan, MD, Wayne State University Karmanos Cancer Institute